NCT02134197 (Clinical Trial/ BAY1129980)

Study Title
Dose-escalation Study of BAY1129980 (NCT02134197)

Trial Description
The purpose of this study is to evaluate:

  • The side effects of BAY1129980 when given every 21 days different dose levels.
  • Determine the dose level of BAY1129980 that should be tested in future clinical research studies.
  • Measure how much BAY1129980 is in the blood at specific times after administration.
  • If treatment with BAY1129980 shows any effect on reducing the tumor growth.
  • If there are specific biomarkers that might be able to explain why some patients respond to treatment and others do not.
  • If treatment with BAY1129980 causes an immune response from the body against the drug (immunogenicity).

This trial is sponsored by Bayer®

Study Data

  • Condition: Neoplasms
  • Interventions:
    • Drugs used in this trial
      • BAY1129980
  • Phase: I
  • Estimated Enrollment: 60
  • Start: May 2014
  • Estimated Completion: December 2018
  • Last verified:September 2017
  • Last updated: September 2017

Study Schematic

Click here to Return to Drug map

Last Editorial review: September 2017
Information based on (NIH/NCI) and other sources.